EBS Emergent BioSolutions Inc.

Emergent BioSolutions to Participate in Virtual Investor Conferences

Emergent BioSolutions to Participate in Virtual Investor Conferences

GAITHERSBURG, Md., June 16, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following virtual investor conferences this month:

  • BMO 2020 Prescriptions for Success Healthcare Virtual Conference

    June 23 – fireside chat at 3:00 pm eastern



  • Three Part Advisors Virtual East Coast IDEAS Investor Conference

    June 24 – pre-recorded presentation available for playback all day beginning at 8:00 am eastern

For these conferences, the company’s webcast presentation may include a discussion of the company's recent business developments as well as its financial results and guidance. The webcasts will be available both live and by replay, accessible from the Emergent website under “Investors.”

About Emergent BioSolutions

Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information visit Find us on LinkedIn and follow us on Twitter @emergentbiosolu and Instagram @life_at_emergent.

Investor Contact:

Robert G. Burrows

Vice President, Investor Relations

240-631-3280

 

Media Contact:

Miko B. Neri

Senior Director, Corporate Communications

240-631-3392

EN
16/06/2020

Underlying

EBSEmergent BioSolutions Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Emergent BioSolutions Inc.

 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Partners with British Columbia to Supply NARCAN®...

Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program WINNIPEG, Manitoba, April 09, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) announced that it has partnered with the B.C. Provincial Health Services Authority (PHSA) to supply NARCAN® Nasal Spray for the province’s Take-Home Naloxone Program (BC THN Program). This order follows an additional investment of $18 million CAD by the B.C. government to expand the BC THN Program to include nasal naloxone. This is an expansion of B.C.’s...

April 9, 2026 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Participates in Upcoming International Preparedn...

Emergent BioSolutions Participates in Upcoming International Preparedness Conferences GAITHERSBURG, Md., April 02, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a global life sciences leader with biodefense and medical countermeasures products, announced today that members of its products business, medical affairs, government and public affairs teams will participate in the following international preparedness conferences: , April 10-11, London, United Kingdom, May 19-21, Arcachon, France, June 9-12, Kuala Lumpur, Malaysia, June 20-22, San Diego, California, United Sta...

April 2, 2026 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Secures over $60 Million in New Contract Award w...

Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures GAITHERSBURG, Md., March 25, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured a contract award valued at approximately $54 million USD to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the Administration for Strategic Preparedness and Response (ASPR), part of the U. S. Department of Health and Human Services (HHS), for smallpox prep...

March 25, 2026 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to ...

Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors GAITHERSBURG, Md., March 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of John D. Fowler, Jr. to its board of directors effective March 1, 2026. Mr. Fowler brings more than three decades of leadership experience across the healthcare and financial services sectors. He will serve on the Audit and Finance Committee. “We’re pleased to welcome John to the board of directors at this important point in the company’s ongoing turnaround and transformation...

March 3, 2026 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financ...

Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results Fourth Quarter 2025 Total Revenues of $148.7 million; Full Year 2025 Total Revenues of $742.9 millionFourth Quarter 2025 Net Loss of $54.6 million and Net Loss Margin of 37%Full Year 2025 Net Income of $52.6 million versus a Net Loss of $190.6 million in the prior yearFull Year 2025 Net Income per diluted share of $0.93 versus a Net Loss per diluted share of $3.60 in the prior yearFull Year 2025 Adjusted Net Income of $86.8 million versus an Adjusted Net Loss of $12.1 million in the prior yearFull Year 2025 Ad...

February 26, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch